NCT06026254View on ClinicalTrials.gov

A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 15, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Solid Tumor, Adult
Interventions
DRUG

IMSA101

Intra-tumoral administration on Days 1 and 15 of every 28-day cycle

DRUG

Immune Checkpoint Inhibitor

Administered according to product label

Trial Locations (2)

85260

Honor Health, Scottsdale

92093

UC San Diego Moores Cancer Center, La Jolla

Sponsors
All Listed Sponsors
lead

ImmuneSensor Therapeutics Inc.

INDUSTRY